Elsevier

European Urology

Volume 45, Issue 5, May 2004, Pages 586-592
European Urology

Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation Therapy

https://doi.org/10.1016/j.eururo.2003.11.032Get rights and content

Abstract

Objective: To evaluate the relationship between neuroendocrine differentiation (NED) status and hormone refractory prostate cancer (HRPC) following hormone therapy based on immunohistochemical study.

Methods: Seventy-two prostate cancer specimens obtained at radical prostatectomy and 21 prostate cancer autopsy specimens from patients who died from HRPC after androgen deprivation therapy were examined for NED status using an antibody against chromogranin A. These specimens were classified into 3 arms: 38 radical prostatectomy specimens from patients with no neoadjuvant hormone therapy (Group 1); 34 from patients with neoadjuvant hormone therapy for 3 to 6 months (Group 2); and 21 autopsy specimens from patients with HRPC following androgen deprivation therapy for more than 1 year (Group 3). Staining of prostatic carcinoma was scored as: 0 = no staining; 1 = staining cells <10%; 2 = staining cells 10–20%; and 3 = staining cells >20%. Differences in scores among the groups were compared using the Kruskal–Wallis rank test. Multivariate analysis using a logistic regression model was performed to examine whether NED status was associated with pathological stage (pT), grade and group.

Results: Forty-nine (53%) tumors had CgA stained cells. NED status increased with longer duration of hormone therapy (p<0.0001). The mean staining score (and standard deviation) was 0.4±0.7 in Group 1, 0.7±0.7 in Group 2, and 1.4±1.1 in Group 3, respectively. By multivariate analysis Group 3 had a relative risk of 5.46 (95%CI 1.28–23.29) for NED compared to the other groups. But other variables were not related to NED. HRPC following Long-term hormonal therapy was the only independent predictor of NED.

Conclusions: The results of this study demonstrated that NED status was significantly increased in patients with HRPC following long-term androgen deprivation therapy, but it could not be discriminate whether the increase of NED is attributable to condition of hormone refractoriness or long-term hormonal therapy.

Introduction

Prostate carcinoma, even at later stages, responds to primary androgen deprivation therapy (either surgical or medical castration) with a response rate of more than 80% [1]. However, more than half of these cancers progress to a hormone-independent status within 16 to 18 months [2]. The elucidation of this conversion from hormone-sensitive status to hormone-insensitive is currently one of the most critical tasks in prostate cancer. A better understanding of the mechanisms of resistance to hormone therapy following androgen deprivation may eventually facilitate the clinical manipulation of such hormone refractory prostate cancer (HRPC) and result in greater survival.

Recently, changes in the differentiation pathway in prostate cancer have been increasingly demonstrated, particularly neuroendocrine (NE) cells as a mechanism in the development of resistance to androgen deprivation therapy [3]. NE cells comprise a highly specialized cell population, containing neurosecretory granules rich in various peptide hormones and biogenic amines such as calcitonin [4], parathyroid hormone-related protein [5], chromogranin A (CgA) [6], [7], serotonin [8], bombesin [9], vascular endothelial growth factors [10] and somatostatin [11]. Approximately 10% of prostatic carcinomas reveal extensive and multifocal NE features by using the endocrine marker CgA [3], [12], [13]. These cancer cells with NE differentiation have been shown to be more abundant after androgen deprivation therapy [6], [14]. Recent studies have indicated that all NE cells in malignant prostatic tissues had no androgen receptors [15], [16], and NE differentiation has been suggested to be associated with HRPC [17]. These previous immunohistochemical studies were performed using radical prostatectomy specimens obtained from early stage patients with or without hormone therapy, or TUR specimens from patients with relatively early progression after androgen ablation therapy, and did not involve substantial hormone refractory prostate cancer specimens such as autopsy specimens obtained from patients whose cause of death was HRPC following hormone treatment. In the current study we confirmed whether NE differentiation status in prostate cancer is substantially associated with HRPC after androgen deprivation therapy based on the comparison between radical prostatectomy and autopsy specimens obtained from HRPC patients.

Section snippets

Patients

Seventy-two patients with prostate cancer that underwent radical prostatectomy between 1992 and 2001 and 21 patients that died from hormone refractory prostate cancer after androgen deprivation therapies in our university hospital between 1983 and 2001 were included in this study. Patient characteristics are found in Table 1. Patients were classified into 3 arms based on different treatments: Group 1 consists of 38 patients who received radical prostatectomy with no neoadjuvant therapy; Group

Results

Most specimens obtained from patients who underwent neoadjuvant hormone therapy and all autopsy specimens showed morphological changes such as atrophy and squamous metaplasia of the non-neoplastic ducts and acini, and cytoplasmic vacuolization, nuclear pyknosis, and fibrosis of the tumor tissue. With respect to morphological features in the immunoreactive neoplastic cells, the highest concentration of NE differentiation appeared in sparse staining or occasional individual positive cells in

Discussion

Increasing attention has been given to NE differentiation in prostate cancer because of its prognostic and therapeutic implications. Serum CgA as a NE differentiation marker has been proposed as an indicator of advanced prostate cancer in some patients who do not have elevated serum PSA [20], [21]. With respect to the correlation between NE differentiation based on immunohistochemical analysis and serum PSA, Deftos et al. [22] measured serum CgA and PSA, and conducted immunohistochemical

References (30)

  • P diSant’Agnese

    Neuroendocrine differentiation in prostatic carcinomas

    Cancer Suppl.

    (1995)
  • C.K Ritchie et al.

    Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis

    Prostate

    (1997)
  • H Bonkhoff et al.

    Relation of endocrine-paracrine cells to proliferation in normal, hyperplastic, neoplastic human prostate

    Prostate

    (1991)
  • A Aprikian et al.

    Neuroendocrine differentiation and bombesin/gastrin-releaseing peptide family of neuropeptides in the progress of human prostate cancer

    Prostate Suppl.

    (1998)
  • M.E Harper et al.

    Vascular endothelial growth factor (VEGF) expression in prostatic tumors and its relationship to neuroendocrine cells

    Br. J. Cancer

    (1996)
  • Cited by (0)

    View full text